Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Expenses:    
Research and development $ 8,395,648 $ 5,853,291
General and administrative 9,344,678 5,074,694
Impairment expenses 1,548,397
Total Operating Expenses 19,288,723 10,927,985
Loss From Operations (19,288,723) (10,927,985)
Other Income (Expense)    
Interest income 6,539 32,495
Change in value of contingent liability (281,713)
Other income 46,494 2,500
Total other income (expense) (228,680) 34,995
Loss Before Provision For Income Taxes (19,517,403) (10,892,990)
Income tax benefit 94,077
Net Loss $ (19,423,326) $ (10,892,990)
Net loss per share, basic and diluted (in Dollars per share) $ (1.04) $ (0.87)
Weighted average shares, basic and diluted (in Shares) 18,588,748 12,463,127